Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| MelasQoL (Melasma elukvaliteedi skaala)× | Skindex-29 (Skin Disease Quality of Life Instrument)× | |
|---|---|---|
| Valdkond | Dermatoloogia | Dermatoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 2006 | 1997 |
| Looja≠ | Cestari TF, Hexsel D | Chren MM, Lasek RJ |
| Tüüp | Self-report | Self-report |
| Algallikas≠ | Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. link ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| Rööpnimetused≠ | Melasma-QoL | Skindex, Skindex-QoL |
| Seotud≠ | 3 | 1 |
| Kokkuvõte≠ | MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGateAndmestik ↗ |
|
|